Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 28, 2010, Pages 12463-12468

  Baldwin, Amy ^a,c   Grueneberg, Dorre A ^b,d   Hellner, Karin ^a   Sawyer, Jacqueline ^b   Grace, Miranda ^a   Li, Wenliang ^b   Harlow, Ed ^b   Munger, Karl ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c St George's University   (United States)

^d Augusta Pharmaceuticals Inc   (United States)

Author keywords

Cancer; E6 oncoprotein; Screening; ShRNA; Viral oncogenesis

Indexed keywords

P21 ACTIVATED KINASE 3; PROTEIN KINASE; PROTEIN P53; SERUM AND GLUCOCORTICOID REGULATED KINASE 2; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; ENZYME INACTIVATION; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; HUMAN CELL CULTURE; ONCOGENE; PRIORITY JOURNAL;

CARCINOMA; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; P21-ACTIVATED KINASES; PAPILLOMAVIRIDAE; PHOSPHOTRANSFERASES; PROTEIN KINASES; PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 77955464738     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1007462107     Document Type: Article

References (42)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890-907.
2. zur Hausen H (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350. (Pubitemid 37328947)
3. Munger K, et al. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460.
4. Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 93:2930-2935. (Pubitemid 26114341)
5. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. (Pubitemid 19066153)
6. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624.
7. Scheffner M, Huibregtse JM, Howley PM (1994) Identification of a human ubiquitinconjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 91:8797-8801.
8. Grueneberg DA, et al. (2008) Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci USA 105:16472-16477.
9. Grueneberg DA, et al. (2008) Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc Natl Acad Sci USA 105:16490-16495.
10. Baldwin A, et al. (2008) Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc Natl Acad Sci USA 105:16478-16483.
11. Bommi-Reddy A, et al. (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105:16484-16489.
12. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA (1987) Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 61:1061-1066.
13. Creek KE, Geslani G, Batova A, Pirisi L (1995) Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv Exp Med Biol 375:117-135.
14. Wan F, et al. (2008) Gene expression changes during HPV-mediated carcinogenesis: A comparison between an in vitro cell model and cervical cancer. Int J Cancer 123:32-40.
15. Liu Y, et al. (1999) Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73:7297-7307. (Pubitemid 29383212)
16. Dobzhansky T (1946) Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31:269-290.
17. Oh J, et al. (2004) Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene 23:5041-5048.
18. Dolma S, Lessnick SL, Hahn WC, Stockwell BR (2003) Identification of genotypeselective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3:285-296.
19. Wang H, Han H, Von Hoff DD (2006) Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 66:9722-9730.
20. Rottmann S, Wang Y, Nasoff M, Deveraux QL, Quon KC (2005) A TRAIL receptordependent synthetic lethal relationship between MYC activation and GSK3beta/ FBW7 loss of function. Proc Natl Acad Sci USA 102:15195-15200. (Pubitemid 41513358)
21. Sarthy AV, et al. (2007) Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 6:269-276.
22. Whitehurst AW, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819.
23. McManus KJ, Barrett IJ, Nouhi Y, Hieter P (2009) Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci USA 106:3276-3281.
24. Brummelkamp TR, Bernards R (2003) New tools for functional mammalian cancer genetics. Nat Rev Cancer 3:781-789. (Pubitemid 37328816)
25. Tucker CL, Fields S (2003) Lethal combinations. Nat Genet 35:204-205.
26. Fraser A (2004) Towards full employment: Using RNAi to find roles for the redundant. Oncogene 23:8346-8352.
27. Willingham AT, Deveraux QL, Hampton GM, Aza-Blanc P (2004) RNAi and HTS: Exploring cancer by systematic loss-of-function. Oncogene 23:8392-8400.
28. Kaelin WG, Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698.
29. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790.
30. Kaelin WG, Jr (2009) Synthetic lethality: A framework for the development of wiser cancer therapeutics. Genome Med 1:99.1-99.6.
31. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB (2009) Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8:3112-3119.
32. Barbie DA, et al. (2009) Systematic RNA interference reveals that oncogenic KRASdriven cancers require TBK1. Nature 462:108-112.
33. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848.
34. Scholl C, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834.
35. Lang F, Cohen P (2001) Regulation and physiological roles of serum- and glucocorticoid- induced protein kinase isoforms. Sci STKE 2001:RE17.
36. Loffing J, Flores SY, Staub O (2006) Sgk kinases and their role in epithelial transport. Annu Rev Physiol 68:461-490.
37. Eswaran J, Soundararajan M, Kumar R, Knapp S (2008) UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci 33:394-403.
38. Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6:459-471.
39. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
40. Bosco EE, et al. (2010) Rac1 inhibition suppresses p53-deficiency mediated lymphomagenesis. Blood 115:3320-3328.
41. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421. (Pubitemid 19229441)
42. Moffat J, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298.